<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009775</url>
  </required_header>
  <id_info>
    <org_study_id>155-CL-034</org_study_id>
    <secondary_id>2009-015738-31</secondary_id>
    <nct_id>NCT01009775</nct_id>
  </id_info>
  <brief_title>A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma</brief_title>
  <official_title>A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate survival, response rate, safety and tolerability of
      YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage
      IV melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will receive YM155 and docetaxel given in a 21-day cycle. The docetaxel dose
      will be established based on the findings of the lead-in portion of the study (Part 1). Once
      the docetaxel dose is established, Part 2 enrollment will begin.

      Part 1:

      Part 1 is a lead-in stage that will confirm if YM155 can be safely administered in
      combination with docetaxel at a specified dose.

      Part 2:

      Subjects enrolled in Part 2 will receive YM155 and docetaxel at the dose established during
      Part 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month Progression-free survival</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (proportion of subjects with complete response or partial response)</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year survival</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after the last subject discontinues treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>After the last non-progressing subject completes 6 months or discontinues the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, physical examinations, vital signs, laboratory assessments and electrocardiograms (ECGs)</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>YM155 plus docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM155</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>YM155 plus docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>YM155 plus docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed Stage III (unresectable) or Stage IV
             melanoma

          -  No prior systemic treatment or Cytotoxic chemotherapy for advanced melanoma (Stage III
             or Stage IV)

          -  If the subject is female, she must be non-pregnant and non-lactating at the Baseline
             Visit. All sexually active males and females of childbearing potential must agree to
             use an adequate method of contraception throughout the study period

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 1

          -  Life expectancy &gt; 12 weeks

          -  At least one measurable target lesion according to Response Evaluation Criteria in
             Solid Tumors ({RECIST} version 1.1)

          -  Subjects with a previous history of non-melanoma malignancy must have undergone
             curative therapy for all prior malignancies and be considered disease free for at
             least 5 years

        Exclusion Criteria:

          -  Major surgery within 21 days of the Baseline Visit

          -  Presence or history of brain metastases

          -  Primary ocular, choroidal or mucosal melanoma

          -  Known history of positive test for Hepatitis B surface Antigen (HsbAg) or Hepatitis C
             antibody or history of positive test for Human Immunodeficiency Virus (HIV)

          -  Hypersensitivity to docetaxel or polysorbate 80

          -  Neuropathy greater than or equal to Grade 2 at Baseline Visit

          -  The subject has been previously treated with YM155

          -  Inadequate marrow, hepatic, and/or renal functions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36619/36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group</name>
      <address>
        <city>Sebastopol</city>
        <state>California</state>
        <zip>95472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109/48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Hospital Cancer Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=562</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <disposition_first_submitted>August 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 4, 2015</disposition_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma, Stage III</keyword>
  <keyword>Melanoma, Stage IV</keyword>
  <keyword>YM 155</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

